Absci Elects New Board Members at Annual Meeting

The latest announcement is out from AbSci ( (ABSI) ).

On June 11, 2025, Absci Corporation held its Annual Meeting of Stockholders, where shareholders voted to elect Frans van Houten and Karen McGinnis as Class I board members and ratified Ernst & Young LLP as the independent accounting firm for 2025. The approval of these proposals is expected to strengthen Absci’s governance and financial oversight, potentially enhancing its industry positioning and stakeholder confidence.

The most recent analyst rating on (ABSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.

Spark’s Take on ABSI Stock

According to Spark, TipRanks’ AI Analyst, ABSI is a Neutral.

AbSci’s overall stock score reflects significant financial challenges and speculative valuation, tempered by promising strategic developments and a solid cash position. Initiatives in AI-driven drug discovery and potential partnerships provide a positive outlook despite ongoing operational inefficiencies.

To see Spark’s full report on ABSI stock, click here.

More about AbSci

Absci Corporation operates in the biotechnology industry, focusing on the development and application of innovative technologies for drug discovery and development.

Average Trading Volume: 3,038,292

Technical Sentiment Signal: Sell

Current Market Cap: $386.5M

See more insights into ABSI stock on TipRanks’ Stock Analysis page.